Skip to main content
Top
Published in: Inflammation Research 4/2012

01-04-2012 | Original Research Paper

Semi-solid topical formulations containing nimesulide-loaded nanocapsules showed in-vivo anti-inflammatory activity in chronic arthritis and fibrovascular tissue models

Authors: Quéli Fernandes Lenz, Sílvia Schaffazick Guterres, Adriana Pohlmann, Marta Palma Alves

Published in: Inflammation Research | Issue 4/2012

Login to get access

Abstract

Objective

To evaluate the anti-inflammatory activity of topical gel containing nimesulide-loaded nanocapsules using experimental models in vivo, and to compare the anti-inflammatory activity of two nimesulide preparations.

Materials

Male Wistar rats (200–250 g) treated with gel containing empty nanocapsules (GEN); gel containing nimesulide in the free form (GNFF) or gel containing nimesulide-loaded nanocapsules (GNN).

Methods

Nanoprecipitation methods were used to prepare the colloidal suspension. In-vivo experimental models of paw edema, acute and chronic arthritis, and granuloma formation were used. The gels were applied topically in all models.

Results

The nanocapsules had an average particle size of 344.6 nm ± 4.33 and a polydispersity index of 0.251 ± 0.002. The models of acute inflammation (paw edema and arthritis) showed that GNFF and GNN were able to inhibit the inflammatory process with similar efficacy. Moreover, nanoencapsulation significantly increased the anti-inflammatory activity of nimesulide in two chronic inflammation models (chronic arthritis and granuloma). The GNFF- and GNN-induced inhibition of inflammation in the chronic arthritis model were 27.75 and 81.5%, respectively. Similarly, GNFF and GNN reduced granuloma formation by 2.82 and 36.66%.

Conclusion

Nanoencapsulation increased the anti-inflammatory activity of topical nimesulide in chronic inflammation models.
Literature
1.
go back to reference Eickhoff WM, Engers DA, Mueller KR. Nanoparticulate NSAID composition. Toxicol Pharmacol. 1995;50:283–9. Eickhoff WM, Engers DA, Mueller KR. Nanoparticulate NSAID composition. Toxicol Pharmacol. 1995;50:283–9.
2.
go back to reference Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res. 1997;46:437–46.PubMedCrossRef Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res. 1997;46:437–46.PubMedCrossRef
3.
go back to reference Giraudel JM, Diquelou A, Laroute V, Lees P, Toutain PL. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. Br J Pharmacol. 2005;146:642–53.PubMedCrossRef Giraudel JM, Diquelou A, Laroute V, Lees P, Toutain PL. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. Br J Pharmacol. 2005;146:642–53.PubMedCrossRef
4.
go back to reference Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120.PubMedCrossRef Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120.PubMedCrossRef
5.
go back to reference Bernardi A, Zilberstein AC, Jager E, Campos MM, Morrone FB, Calixto JB, et al. Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol. 2009;158:1104–11.PubMedCrossRef Bernardi A, Zilberstein AC, Jager E, Campos MM, Morrone FB, Calixto JB, et al. Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol. 2009;158:1104–11.PubMedCrossRef
6.
go back to reference Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther. 2005;107:139–54.PubMedCrossRef Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther. 2005;107:139–54.PubMedCrossRef
7.
go back to reference Rainsford KD. Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rheumatology (Oxford) 1999; 38 Suppl 1:4–10. Rainsford KD. Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rheumatology (Oxford) 1999; 38 Suppl 1:4–10.
8.
go back to reference Weder JE, Dillon CT, Hambley TW, Kennedy BJ, Lay PA, Biffin JR, et al. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. Coord Chem Rev. 2002;232:95–126.CrossRef Weder JE, Dillon CT, Hambley TW, Kennedy BJ, Lay PA, Biffin JR, et al. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. Coord Chem Rev. 2002;232:95–126.CrossRef
9.
go back to reference Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003;327:18–22.PubMedCrossRef Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003;327:18–22.PubMedCrossRef
10.
go back to reference Whittle BJ. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fund Clin Pharmacol. 2003;17:301–13.CrossRef Whittle BJ. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fund Clin Pharmacol. 2003;17:301–13.CrossRef
11.
go back to reference Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide. J Pharm Pharm Sci. 2002;5:220–5.PubMed Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide. J Pharm Pharm Sci. 2002;5:220–5.PubMed
12.
go back to reference Van Steenbergen W, Peeters P, De Bondt J, Staessen D, Buscher H, Laporta T, et al. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol. 1998;29:135–41.PubMedCrossRef Van Steenbergen W, Peeters P, De Bondt J, Staessen D, Buscher H, Laporta T, et al. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol. 1998;29:135–41.PubMedCrossRef
13.
go back to reference Bansal SS, Joshi A, Bansal AK. New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging. 2007;24:441–51.PubMedCrossRef Bansal SS, Joshi A, Bansal AK. New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging. 2007;24:441–51.PubMedCrossRef
14.
go back to reference Schaffazick SR, Guterres SS. Caracterização e estabilidade físico-química de sistemas poliméricos nanoparticulados para administração de fármacos. Quim Nova. 2003;26:726–37.CrossRef Schaffazick SR, Guterres SS. Caracterização e estabilidade físico-química de sistemas poliméricos nanoparticulados para administração de fármacos. Quim Nova. 2003;26:726–37.CrossRef
15.
go back to reference Alves MP, Scarrone AL, Santos M, Pohlmann AR, Guterres SS. Human skin penetration and distribution of nimesulide from hydrophilic gels containing nanocarriers. Int J Pharm. 2007;341:215–20.PubMedCrossRef Alves MP, Scarrone AL, Santos M, Pohlmann AR, Guterres SS. Human skin penetration and distribution of nimesulide from hydrophilic gels containing nanocarriers. Int J Pharm. 2007;341:215–20.PubMedCrossRef
16.
go back to reference Pohlmann AR, Mezzalira G, Cruz L, Soares LU, Silveira NP, Guterres SS. Structural model of polymeric nanospheres indomethacin ethyl ester and in vivo antiedematogenic activity. Int J Nanotechnol. 2007;4:454–67.CrossRef Pohlmann AR, Mezzalira G, Cruz L, Soares LU, Silveira NP, Guterres SS. Structural model of polymeric nanospheres indomethacin ethyl ester and in vivo antiedematogenic activity. Int J Nanotechnol. 2007;4:454–67.CrossRef
17.
go back to reference Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345:163–71.PubMedCrossRef Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345:163–71.PubMedCrossRef
18.
go back to reference Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295–304.PubMedCrossRef Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295–304.PubMedCrossRef
19.
go back to reference Gupta SK, Prakash J, Awor L, Joshi S, Velpandian T, Sengupta S. Anti-inflammatory activity of topical nimesulide gel in various experimental models. Inflamm Res. 1996;45:590–2.PubMedCrossRef Gupta SK, Prakash J, Awor L, Joshi S, Velpandian T, Sengupta S. Anti-inflammatory activity of topical nimesulide gel in various experimental models. Inflamm Res. 1996;45:590–2.PubMedCrossRef
20.
go back to reference Kontogiorgis CA, Hadjipavlou-Litina DJ. Non steroidal anti-inflammatory and anti-allergy agents. Curr Med Chem. 2002;9:89–98.PubMed Kontogiorgis CA, Hadjipavlou-Litina DJ. Non steroidal anti-inflammatory and anti-allergy agents. Curr Med Chem. 2002;9:89–98.PubMed
21.
go back to reference Strauss KI. Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain. Brain Behav Immun. 2008;22:285–98.PubMedCrossRef Strauss KI. Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain. Brain Behav Immun. 2008;22:285–98.PubMedCrossRef
22.
go back to reference Fessi H, Puisieux F, Defissaguet J. Procédé de préparation des systémes collïdaux dispersibles d’une substance sous forme de nanocapsules. European Patent 0274961A1, 1988. Fessi H, Puisieux F, Defissaguet J. Procédé de préparation des systémes collïdaux dispersibles d’une substance sous forme de nanocapsules. European Patent 0274961A1, 1988.
23.
go back to reference Alves PM, Pohlmann AR, Guterres SS. Semisolid topical formulations containing nimesulide-loaded nanocapsules, nanospheres or nanoemulsion: development and rheological characterization. Pharmazie. 2005;60:900–4.PubMed Alves PM, Pohlmann AR, Guterres SS. Semisolid topical formulations containing nimesulide-loaded nanocapsules, nanospheres or nanoemulsion: development and rheological characterization. Pharmazie. 2005;60:900–4.PubMed
24.
go back to reference Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544–7.PubMed Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544–7.PubMed
25.
go back to reference Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001;53:597–652.PubMed Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001;53:597–652.PubMed
26.
go back to reference Brand DD. Rodent models of rheumatoid arthritis. Comp Med. 2005;55:114–22.PubMed Brand DD. Rodent models of rheumatoid arthritis. Comp Med. 2005;55:114–22.PubMed
27.
go back to reference Bastos LF, Merlo LA, Rocha LT, Coelho MM. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. Eur J Pharmacol. 2007;576:171–9.PubMedCrossRef Bastos LF, Merlo LA, Rocha LT, Coelho MM. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. Eur J Pharmacol. 2007;576:171–9.PubMedCrossRef
28.
go back to reference Bouchemal K, Briancon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm. 2004;280:241–51.PubMedCrossRef Bouchemal K, Briancon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm. 2004;280:241–51.PubMedCrossRef
29.
go back to reference Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm. 2003;258:141–51.PubMedCrossRef Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm. 2003;258:141–51.PubMedCrossRef
30.
go back to reference Cruz L, Soares LU, Costa TD, Mezzalira G, da Silveira NP, Guterres SS, et al. Diffusion and mathematical modeling of release profiles from nanocarriers. Int J Pharm. 2006;313:198–205.PubMedCrossRef Cruz L, Soares LU, Costa TD, Mezzalira G, da Silveira NP, Guterres SS, et al. Diffusion and mathematical modeling of release profiles from nanocarriers. Int J Pharm. 2006;313:198–205.PubMedCrossRef
31.
go back to reference Poletto FS, Silveira RP, Fiel LA, Donida B, Rizzi M, Guterres SS, et al. Size-control of poly (epsilon-caprolactone) nanospheres by the interface effect of ethanol on the primary emulsion droplets. J Nanosci Nanotechnol. 2009;9:4933–41.PubMedCrossRef Poletto FS, Silveira RP, Fiel LA, Donida B, Rizzi M, Guterres SS, et al. Size-control of poly (epsilon-caprolactone) nanospheres by the interface effect of ethanol on the primary emulsion droplets. J Nanosci Nanotechnol. 2009;9:4933–41.PubMedCrossRef
32.
go back to reference Jager E, Venturini CG, Poletto FS, Colome LM, Pohlmann JP, Bernardi A, et al. Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J Biomed Nanotechnol. 2009;5:130–40.PubMedCrossRef Jager E, Venturini CG, Poletto FS, Colome LM, Pohlmann JP, Bernardi A, et al. Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J Biomed Nanotechnol. 2009;5:130–40.PubMedCrossRef
Metadata
Title
Semi-solid topical formulations containing nimesulide-loaded nanocapsules showed in-vivo anti-inflammatory activity in chronic arthritis and fibrovascular tissue models
Authors
Quéli Fernandes Lenz
Sílvia Schaffazick Guterres
Adriana Pohlmann
Marta Palma Alves
Publication date
01-04-2012
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 4/2012
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-011-0411-9

Other articles of this Issue 4/2012

Inflammation Research 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine